Author:
PUTRIANA NORISCA ALIZA,RUSDIANA TAOFIK,ROSTINAWATI TINA,AKBAR MOHAMMAD RIZKI,MEGANTARA SANDRA,HIDAYANTI SABRANAH
Abstract
Objective: This study aimed to predict the effect of SNPs CYP2C9 s on the metabolic activity of S-warfarin in the body.
Methods: Molecular modeling was performed to obtain SNPs CYP2C9 and molecular docking was performed to predict the effect of SNPs CYP2C9 on the metabolic activity of S-warfarin.
Results: The results showed that wild-type CYP2C9 had the strongest binding affinity (∆G: -9.76 kcal/mol), indicating that wild-type CYP2C9 had the best metabolic activity compared to SNPs CYP2C9. There was a decrease in hydrogen bond formation in SNPs CYP2C9 and an increase in the distance between C7 S-warfarin and Fe-Heme in CYP2C9 SNPs when compared to wild-type CYP2C9
Conclusion: The decrease in binding affinity, decrease in hydrogen bond formation, and an increase in the distance between C7 S-warfarin and Fe-Heme on SNPs CYP2C9 indicated that SNPs CYP2C9 had decreased metabolic activity against S-warfarin which led to an increased risk of bleeding.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference8 articles.
1. Badan Pengawas Obat dan. Antikoagulan Oral. Available from: https://pionas.pom.go.ID/ioni/bab-2-sistem-kardiovaskuler-0/26-antikoagulan-dan-protamin/261-antikoagulan-oral.
2. Pavani A, Naushad SM, Stanley BA, Kamakshi RG, Abinaya K, Amaresh Rao MA. Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin. Pharmacogenomics. 2015;16(4):393-400. doi: 10.2217/pgs.14.185, PMID 25823787.
3. PubChem. CYP2C9 cytochrome P450 family 2 subfamily C member 9 [Homo sapiens (human)]; 2022. Available from: https://www.ncbi.nlm.nih.gov/gene/1559. [Last accessed on 29 Nov 2022]
4. Yadav A, Katara P. In silico mining of SNP-effects on structural properties of CYP2C9 and their consequences. Int Conf Bioinform Syst Biol BSB 2018. p. 136-40. doi: 10.1109/BSB.2018.8770585.
5. Parikh SJ, Evans CM, Obi JO, Zhang Q, Maekawa K, Glass KC. Structure of cytochrome P450 2C9*2 in complex with losartan: insights into the effect of genetic polymorphism. Mol Pharmacol. 2020;98(5):529-39. doi: 10.1124/molpharm.120.000042, PMID 32938720.